Viread (Tenofovir)

DO. SEE. HEAR. KNOW. Visit TheBody.com's 2008 World AIDS Day Center >>

HIV/AIDS Basics & Prevention

Just Diagnosed

HIV Treatment

Living With HIV

AIDS Policy & Activism

HIV Around the World

Conference Coverage

Viread (Tenofovir)

The Basics | News | Research | Tenofovir for HIV Prevention

Brand Name:	Viread
Generic Name:	Tenofovir disoproxil fumarate, TDF
Adult Single Dose:	One 300-mg tablet (once a day)
Food & Liquid Restrictions:	None
Drug Class:	NRTI

The Basics

An Overview of Viread (Tenofovir) (Regularly Updated)
To read PDF, click here
From U.S. National Institutes of Health
Viread (Tenofovir Disoproxil Fumarate, TDF) (January/February 2008)
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
Viread (Tenofovir) (September 28, 2007)
Basic information on dosing schedules and side effects.
From U.S. Department of Veterans Affairs
Tenofovir (Viread) (July 23, 2007)
To read PDF, click here
From AIDS InfoNet
Patient Information About Viread (Tenofovir) (PDF) (May 2007)
From Gilead Sciences, Inc.
Tenofovir (Viread) (August 15, 2006)
From AIDS Treatment Data Network
Viread (Tenofovir) (November 2005)
To read PDF, click here
From The Center for AIDS
Drug Interactions: Tenofovir (August 2004)
From Project Inform
Tenofovir: New Kind of Anti-HIV Drug Gets Approved (March 2002)
In Project Inform Perspective, from Project Inform
Tenofovir DF 300 mg Consistently Demonstrates Anti-HIV Activity Regardless of Baseline Demographic Characteristics in Antiretroviral Experienced HIV-1-Infected Patients (October 29, 2001)
In 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, from The Body PRO
FDA Briefing Documents on Tenofovir (October 3, 2001)
From U.S. Food and Drug Administration
Position Paper on NDA 21-356 for Gilead Sciences' Viread Brand Tenofovir Disoproxil Fumarate (October 3, 2001)
In TAGline, from Treatment Action Group
New Drugs in Development: Very Viread (Fall 2001)
A look at the drug's indications, resistance profile and some clinical trial results.
To read PDF, click here
In CRIA Update, from AIDS Community Research Initiative of America

News

FDA Approves Gilead's Antiretroviral Viread for Use as Hepatitis B Treatment (August 13, 2008)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
Gilead Sciences May Lose Patent for Viread (January 25, 2008)
Looser patent laws could mean generic version of Tenofovir to come.
In Housing Works AIDS Issues Update, from Housing Works
U.S. Patent Agency to Review Gilead's Claim on Tenofovir (July 20, 2007)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
Gilead Lowers Its No-Profit Drug Prices for Truvada, Viread (August 30, 2005)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
Viread (Tenofovir Disoproxil Fumarate) Labeling Revision (May 13, 2005)
Among the revisions is updated information regarding drug resistance and long-term effects on bone mineral density.
From U.S. Food and Drug Administration
Warning on Two Specific 3-Drug Regimens: Viread + Videx + Either Sustiva or Viramune (November 23, 2004)
A brief comment on the recently issued warning that both regimens frequently fail.
In AIDS Treatment News, from AIDS Treatment News
Two New Fixed-Dose Combinations Approved (August 2, 2004)
From U.S. Food and Drug Administration
Food and Drug Administration to Expedite Decision on Emtricitabine/Tenofovir Pill (May 18, 2004)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
Drug Development News: Fixed-Dose Combinations (May/June 2004)
The Food and Drug Administration's fast-track approval process for fixed-dose combinations is about to bear fruit.
In GMHC Treatment Issues, from Gay Men's Health Crisis
Gilead Sciences First-Quarter Profits Driven by Increase in Sales of Antiretroviral Viread (April 26, 2004)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
Atazanavir (Reyataz): New Recommendations if Combined With Tenofovir (Viread) -- and Warning on Viagra, Cialis, and Levitra (March 26, 2004)
New warnings on drug-drug interactions are noted in the prescribing information for atazanavir.
In AIDS Treatment News, from AIDS Treatment News
Revised Labeling for Viread (Tenofovir Disoproxil Fumarate) 300 mg Tablets (November 4, 2003)
From U.S. Food and Drug Administration
Gilead Warns Against Use of Triple-NRTI Regimen 3TC, ddI, Tenofovir (October 14, 2003)
To read PDF, click here
From U.S. Food and Drug Administration
Atazanavir/Tenofovir Combo Should Be Boosted With Ritonavir (August 8, 2003)
From U.S. Food and Drug Administration
FDA Orders Gilead for Second Time to Stop Downplaying Risks, Inflating Benefits of Antiretroviral Drug Viread (August 8, 2003)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
U.S. Approves Emtriva; Gilead Hopes Viread/Emtriva Combo Will Compete With Combivir (July 3, 2003)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
European Union Gives Thumbs-Up to Tenofovir Use in Treatment-Naive Patients (May 28, 2003)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
HIV-Positive Man Dies of Kidney Failure and Lactic Acidosis Due to Tenofovir/ddI Interaction (April 8, 2003)
From aidsmap.com
Three French Cases of Tenofovir Kidney Toxicity Reported Amongst HIV-Positive Patients (April 8, 2003)
From aidsmap.com
Gilead Offers Tenofovir to Developing Countries at Cost (April 4, 2003)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
New Safety Information -- Viread Co-Administration With Videx (September 30, 2002)
From U.S. Food and Drug Administration
ddI-Tenofovir Interaction Warning (PDF) (May 7, 2002)
From Bristol-Myers Squibb Company
More Uses for Tenofovir? (January 25, 2002)
The drug's usefulness in pregnant women, as a microbicide or as first-line therapy has yet to be thoroughly investigated.
To read PDF, click here
In AIDS Treatment News, from AIDS Treatment News
Nutrient Deficiency Associated With New HIV Medication (December 2001)
In Survival News, from AIDS Survival Project
Tenofovir (Viread), First Novel Antiviral Agent in Six Years, Approved by FDA (November 2001)
In TAGline, from Treatment Action Group
FDA Approves Viread for HIV-1 Infection (October 29, 2001)
From U.S. Food and Drug Administration
Tenofovir Approved: Broad Indication (October 26, 2001)
To read PDF, click here
In AIDS Treatment News, from AIDS Treatment News
Tenofovir: FDA Hearing on Important New Antiretroviral (October 19, 2001)
To read PDF, click here
In AIDS Treatment News, from AIDS Treatment News
Expanded Access to Tenofovir (October 9, 2001)
From Canadian AIDS Treatment Information Exchange
Activists Call for Immediate Approval of Viread Tenofovir DF (October 3, 2001)
In TAGline, from Treatment Action Group
Tenofovir: FDA Hearing October 3, Public Comment Deadlines September 26 (August 24, 2001)
To read PDF, click here
In AIDS Treatment News, from AIDS Treatment News
Tenofovir DF on the Horizon (August/September 2001)
In Positive Living, from AIDS Project Los Angeles
Tenofovir: Gilead Applies for Approval; Expanded Access Liberalized (May 11, 2001)
To read PDF, click here
In AIDS Treatment News, from AIDS Treatment News
Gilead Provides Expanded Access Program for Tenofovir (March 2001)
To read PDF, click here
In Project Inform Perspective, from Project Inform
Tenofovir Expanded Access (Spring 2001)
To read PDF, click here
In CRIA Update, from AIDS Community Research Initiative of America
Tenofovir DF Expanded Access (February 23, 2001)
In AIDS Treatment News, from AIDS Treatment News
Early Access Program Opened for Nucleotide Analogue Tenofovir (February 22, 2001)
In STEP Ezine, from Seattle Treatment Education Project
PMPA (Tenofovir) -- Access Programs in Development (December 1999)
In Body Positive, from Body Positive
Tenofovir Compassionate Use Program (September/October 1999)
In GMHC Treatment Issues, from Gay Men's Health Crisis
PMPA in Perspective (December 1, 1995)
In AIDS Treatment News, from AIDS Treatment News

The Body is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.